Cargando…
Therapy for advanced cholangiocarcinoma: Current knowledge and future potential
Cholangiocarcinoma (CCA) is a biliary epithelial tumour that can emerge at any point in the biliary tree. It is commonly classified based on its anatomical site of development into intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PCC) and distal cholangiocarcinoma (DCC), each of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812297/ https://www.ncbi.nlm.nih.gov/pubmed/33277810 http://dx.doi.org/10.1111/jcmm.16151 |
_version_ | 1783637641308143616 |
---|---|
author | Wang, Mingxun Chen, Ziyan Guo, Pengyi Wang, Yi Chen, Gang |
author_facet | Wang, Mingxun Chen, Ziyan Guo, Pengyi Wang, Yi Chen, Gang |
author_sort | Wang, Mingxun |
collection | PubMed |
description | Cholangiocarcinoma (CCA) is a biliary epithelial tumour that can emerge at any point in the biliary tree. It is commonly classified based on its anatomical site of development into intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PCC) and distal cholangiocarcinoma (DCC), each of which is associated with varying patient demographics, molecular characteristics and treatment options. CCA patients have poor overall prognoses and 5‐year survival rates. Additionally, CCA is often diagnosed at an advanced stage, with surgical treatment restricted to early‐stage disease. Owing to an increase in the incidence of ICC, that of CCA is also on the rise, with a corresponding increase in the associated mortality, particularly in South America and Asia. Therefore, the development of an effective treatment is crucial to improve the survival of CCA patients. We aimed to systematically review the current understanding of advanced CCA treatment and discuss potential effective strategies. |
format | Online Article Text |
id | pubmed-7812297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78122972021-01-22 Therapy for advanced cholangiocarcinoma: Current knowledge and future potential Wang, Mingxun Chen, Ziyan Guo, Pengyi Wang, Yi Chen, Gang J Cell Mol Med Reviews Cholangiocarcinoma (CCA) is a biliary epithelial tumour that can emerge at any point in the biliary tree. It is commonly classified based on its anatomical site of development into intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PCC) and distal cholangiocarcinoma (DCC), each of which is associated with varying patient demographics, molecular characteristics and treatment options. CCA patients have poor overall prognoses and 5‐year survival rates. Additionally, CCA is often diagnosed at an advanced stage, with surgical treatment restricted to early‐stage disease. Owing to an increase in the incidence of ICC, that of CCA is also on the rise, with a corresponding increase in the associated mortality, particularly in South America and Asia. Therefore, the development of an effective treatment is crucial to improve the survival of CCA patients. We aimed to systematically review the current understanding of advanced CCA treatment and discuss potential effective strategies. John Wiley and Sons Inc. 2020-12-04 2021-01 /pmc/articles/PMC7812297/ /pubmed/33277810 http://dx.doi.org/10.1111/jcmm.16151 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Wang, Mingxun Chen, Ziyan Guo, Pengyi Wang, Yi Chen, Gang Therapy for advanced cholangiocarcinoma: Current knowledge and future potential |
title | Therapy for advanced cholangiocarcinoma: Current knowledge and future potential |
title_full | Therapy for advanced cholangiocarcinoma: Current knowledge and future potential |
title_fullStr | Therapy for advanced cholangiocarcinoma: Current knowledge and future potential |
title_full_unstemmed | Therapy for advanced cholangiocarcinoma: Current knowledge and future potential |
title_short | Therapy for advanced cholangiocarcinoma: Current knowledge and future potential |
title_sort | therapy for advanced cholangiocarcinoma: current knowledge and future potential |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812297/ https://www.ncbi.nlm.nih.gov/pubmed/33277810 http://dx.doi.org/10.1111/jcmm.16151 |
work_keys_str_mv | AT wangmingxun therapyforadvancedcholangiocarcinomacurrentknowledgeandfuturepotential AT chenziyan therapyforadvancedcholangiocarcinomacurrentknowledgeandfuturepotential AT guopengyi therapyforadvancedcholangiocarcinomacurrentknowledgeandfuturepotential AT wangyi therapyforadvancedcholangiocarcinomacurrentknowledgeandfuturepotential AT chengang therapyforadvancedcholangiocarcinomacurrentknowledgeandfuturepotential |